Tags : Expand

Thermo Fisher Expands its Direct-to-Patient Service Offerings

Shots: The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates The company’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched in early 2020 to ensure that clinical trial patients have uninterrupted access to […]Read More

Eisai and Cogstate Expand their Agreement to Develop and Commercialize

Shots: Eisai gets the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the CBB for use in healthcare and other markets. The agreement allows the two companies to replicate the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital […]Read More

IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid

Shots: The companies have expanded their clinical trial collaboration and supply agreement for IDE196 and crizotinib. The study will evaluate combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including MUM, skin melanoma, lung cancer, and colorectal cancer The two global companies have established JDC and there will be joint decision […]Read More

Evotec and Centogene Expand their Collaboration to Target Gaucher Disease

Shots: The two companies will work together to research, discover, and develop therapeutic options related to the deficiency of the protein GBA which is a gene linked to Gaucher disease The collaboration will combine Evotec’s iPSC platform and drug discovery and development capabilities with Centogene’s global rare disease platform, including iPSC lines The collaboration follows […]Read More

Gilead Expands its Oncology Collaboration with Tango for ~$6.3B

Shots: Tango to receive $125M up front, $20M as equity investment, up to $410M/ program as an opt-in, extension, and milestones along with royalties on sales of the products. If Tango opts to co-develop and co-promote the product, the parties will equally split profits/losses and development costs in the US and will receive milestones and […]Read More

Olympus to Acquire Arc Medical Design for Expanding its Product

Shots: The acquisition will expand Olympus’ offerings in GI therapeutic devices and the development of advanced colonoscopy tools with the aim of improving early detection and treatment of CRC Olympus will obtain full rights to Arc Medical Design’s medical products and will convert its current exclusive distribution rights of Endocuff Vision to a full acquisition […]Read More

Baxter and Ayogo Expand their Partnership to Advance Digital Health

Shots: The companies expanded the collaboration to support the needs of patients with kidney disease via digital health solutions. The agreement integrates Ayogo’s LifePlan digital platform with Baxter’s expertise in renal care to develop mobile apps and digital solutions that bring personalized and timely support to patients with kidney failure Baxter made an equity investment […]Read More

AstraZeneca Signs an Agreement with Emergent BioSolutions to Expand Manufacturing

Shots: Emergent will provide CDMO services for AstraZeneca’ AZD1222. The agreement valued ~174M through 2021 and follows an $87M agreement signed in June for development services, performance and process qualification, raw materials, and an initial capacity reservation The two companies may enter additional commercial manufacturing agreement as the candidate progresses over three years through Emergent’s […]Read More

Roche and Cipla Expand Their 2018 Agreement to Improve Access

Shots: Cipla expands partnership with Roche to improve access to key oncology medicines which include Herclon (trastuzumab), Avastin (bevacizumab) and Ristova (rituximab) in India. Cipla will be responsible for the marketing and distribution of Roche’s key products In Feb’2018, the two companies collaborated for the promotion and distribution of Actemra (tocilizumab) and other products  The […]Read More

Foundation Medicine Acquires Lexent to Expand its Liquid Biopsy Platforms

Shots: Foundation Medicine acquires Lexent to accelerate the Foundation’s R&D strategy and expand its existing liquid biopsy platforms to advance cancer care for patients. The acquisition will boost Foundation Medicine’s capabilities to support adaptive clinical trial designs and accelerate therapeutic development in both early/ late-stage disease The addition of Lexent’s technology to Foundation’s portfolio of […]Read More